lead plaintiff deadline

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.

Class action lawsuit filed against $SNOW alleges securities fraud over material nondisclosure of product changes and CEO transition, spanning June 2023-February 2024.

Securities fraud class actions filed against PayPal, NuScale, Corcept, and Navan. Investors must file lead plaintiff motions by April 20-24, 2026.

Law firm Levi & Korsinsky files class action against Boston Scientific, citing misleading statements. Stock tumbled 17.6% after disappointing Q4 2025 earnings and weak 2026 guidance.

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

uniQure faces shareholder lawsuit alleging false statements on FDA approval and study design. Lead plaintiff deadline: April 13, 2026.

Class action lawsuit alleges CoreWeave made materially false statements about demand and supplier risks between March-December 2025. Lead plaintiff deadline: March 13, 2026.

Four publicly-traded companies face securities fraud class actions with April 2026 lead plaintiff deadlines. Allegations include false partnership claims, overstated DOE funding, and improper asset valuations.

Rosen Law Firm sues Varonis Systems for allegedly misrepresenting ARR projections and SaaS conversion capabilities. Eligible shareholders have until March 9, 2026 to pursue claims.

Apollo Global Management faces securities class action lawsuit over alleged Epstein disclosure failures. Lead plaintiff deadline set for May 1, 2026.

uniQure faces securities class action lawsuit alleging misstatements about Pivotal Study design and FDA approval. Lead plaintiff deadline: April 13, 2026.

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.

Enphase Energy faces class action lawsuit over failure to disclose inventory management limitations and tax credit risks. Lead plaintiff deadline: April 20, 2026.

Kyndryl ($KD) faces class action lawsuit after 55% stock decline following February disclosure of material weaknesses in internal controls and delayed 10-Q filing.

Rosen Law Firm urges Paysafe investors to join securities class action alleging disclosure failures, with April 7, 2026 lead plaintiff deadline.

Navan faces securities class action over failing to disclose $95M sales expense surge (39% increase) in Q3 2025. Investors with $100K+ losses have until April 24, 2026 to file.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.

CoreWeave ($CRWV) faces securities class action lawsuit alleging false demand statements and understated supplier risks. Lead plaintiff deadline: March 13, 2026.